CNS Pharmaceuticals (FRA:BE50) Change In Receivables: €0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BE50 CNS Pharmaceuticals Inc FRA:BE50
35 GF Score
Price €0.61
! 1 Warning Sign
View Full Analysis

What is CNS Pharmaceuticals Change In Receivables?

CNS Pharmaceuticals FRA:BE50 35 Change In Receivables is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:BE50 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

CNS Pharmaceuticals's change in receivables for the quarter that ended in Jun. 2026 was €0.00 Mil. It means CNS Pharmaceuticals's Accounts Receivable stayed the same from Mar. 2026 to Jun. 2026 .

CNS Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2025 was €0.00 Mil. It means CNS Pharmaceuticals's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

CNS Pharmaceuticals's Accounts Receivable for the quarter that ended in Jun. 2026 was €0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. CNS Pharmaceuticals's liquidation value for the three months ended in Jun. 2026 was €14.10 Mil.

CNS Pharmaceuticals  (FRA:BE50) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

CNS Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0*91
=

2. In Ben Graham's calculation of liquidation value, CNS Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

CNS Pharmaceuticals's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=17.347-3.245+0.75 * 0+0.5 * 0
=14.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CNS Pharmaceuticals Change In Receivables Related Terms

CNS Pharmaceuticals Change In Receivables Historical Data

* Premium members only.

The historical data trend for CNS Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CNS Pharmaceuticals Change In Receivables Chart

CNS Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

CNS Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:BE50
35GF Score
CNS Pharmaceuticals Inc FRA:BE50
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CNS Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of €0.00 Mil mean?
CNS Pharmaceuticals (FRA:BE50) has a Change In Receivables of €0.00 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for CNS Pharmaceuticals and its competitors.
Is CNS Pharmaceuticals' Change In Receivables too high?
CNS Pharmaceuticals' current Change In Receivables is €0.00 Mil. Overall, CNS Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does CNS Pharmaceuticals' Change In Receivables compare to ALZN and SNGX?
CNS Pharmaceuticals' Change In Receivables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for CNS Pharmaceuticals and its competitors. CNS Pharmaceuticals's current Change In Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNS Pharmaceuticals stock overvalued right now?
CNS Pharmaceuticals (FRA:BE50) has a current Change In Receivables of €0.00 Mil. The current Change In Receivables is €0.00 Mil. CNS Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For CNS Pharmaceuticals (FRA:BE50), the current Change In Receivables is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CNS Pharmaceuticals Business Description

Other Exchanges CNSP:USA
Address 2100 West Loop South, Suite 900, Houston, TX, USA, 77027
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
35GF Score

Get the complete analysis for FRA:BE50

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.61
Price